On February 28, 2025, Medlander (688273.SH) independently developed Class II "Ultrasonic Therapy Device" officially approved by Jiangsu Provincial Medical Products Administration, Registration No.: Su Medical Device Registration Approval 20252090332,It has become the third ultrasound therapy device approved in China for the indication of "tightening and lifting facial skin and removing wrinkles."
It is reported that,The ultrasonic therapy device consists of a main unit, a foot pedal switch, a handle, and a treatment head.Using Ultrasonic Energy, without causing tissue degeneration, it helps toFacial Skin Tightening and Lifting, Wrinkle Removal。Medlander asChina Intelligent Pelvic Floor Reproductive Rehabilitation Diagnosis and TreatmentThe leading brand in the industry, focusing onPelvic Floor Treatment DeviceResearch and development, production, sales and service, while providingFemale Reproductive Anti-AgingComprehensive solutions in the field; with 14 national, provincial, and municipal R&D platforms, 239 authorized intellectual property rights, and participation in drafting 5 industry standards; main products have been sold in over 20 countries worldwide, treating more than 600,000 patients annually, ranking first in market share in China’s细分 industry.At the same time, the company will focus on pelvic floor rehabilitation and move towards"More Serious" and "More Consumer-Oriented"Development in Two Major Fields: In terms of consumer healthcare, the company actively deploys in-home solutions.Medical Devices and Anti-Aging Field, offering private testing + anti-aging, reproductive + facial integrated solutions to meet the health and beauty needs of women, and has successively invested inYisu Medical, Aotong Laser, Xiaofu Technology, the layout of medical beauty products has been completed, and the strategic planning for health and beauty has been preliminarily finished, laying a foundation for the medium and long-term development of the company.As of now, two Class II ultrasound therapy devices for "skin tightening, lifting, and wrinkle removal" on the face have been approved in China, respectively.Exclusively Distributed by Jingyan BiotechMFU pro"MeramayUltrasonic Scalpel(HN Medical Device Registration No. 20242090073) andGuizhou Perlead MedicalBolidaPolida®"Platinum Ultrasound Cannon"(Qianjiang Medical Device Registration Certificate No. 20242090048),Medlander's "Ultrasonic Therapy Device" is approved in China.The 3rd-Generation Ultrasound Therapy Device for Medical Aesthetic Compliance Indications。
Medlander Medical Technology Inc. was founded inFounded in 2013, Medlander Medical Technology Inc. is a solution provider in China for physical rehabilitation intervention technologies covering the entire life cycle of women. The company is mainly engaged in the research and development, production, and sales of products related to pelvic floor and postpartum rehabilitation, forming a series of medical pelvic floor, postpartum recovery, and home-use products. It has been successively recognized as a national-level specialized, refined, distinctive, and innovative "little giant" enterprise, and a demonstration enterprise of a single-item champion in national manufacturing. On August 11, 2022, the company was successfully listed on the STAR Market, with the stock code: 688273.
MedlanderMedlanderBuilding on the foundation of pelvic floor and postpartum rehabilitation, the company further expands into fields such as reproductive rehabilitation, sports rehabilitation, nutrition, and health management, striving to become a world-class healthcare company dedicated to women's health and beauty.It now has product lines including pelvic floor and postpartum rehabilitation equipment, reproductive rehabilitation equipment, consumables and accessories, health management information systems, etc., which are widely used in medical and health fields such as obstetrics and gynecology, pelvic floor rehabilitation, reproductive rehabilitation, urology and proctology, and physical examination.
In the field of postpartum rehabilitation, mainly targeting gynecological and obstetric rehabilitation, postpartum recovery, and the diagnosis and treatment of pelvic floor functional disorders. Products mainly include: biofeedback stimulators, pelvic floor ultrasound, magnetic stimulators, high-frequency evaluation and electrocautery devices, pelvic floor training devices, portable postpartum recovery devices, and home-use pelvic floor rehabilitation therapy devices, which are widely used in departments such as gynecology, pelvic floor rehabilitation centers, urology, and proctology in hospitals.In the field of reproductive rehabilitation, mainly for post-abortion surgery, post-hysteroscopic surgery, infertility, and adjuvant treatment of premature ovarian failure, etc. The products mainly include: biofeedback stimulators, high-frequency evaluation and electrocautery devices, ultrasonic uterine rehabilitation devices, electro-ultrasound therapy devices, etc., applied in the gynecology, obstetrics, reproductive centers of hospitals, as well as medical cosmetic institutions and other fields.In the field of sports rehabilitation, mainly targeting motor function disorders and hand function assessment and rehabilitation for people with cerebral palsy and post-stroke. The products mainly include: Finger Joint Rehabilitation Assessment System, Portable Hand Function Rehabilitation Assessment System, Hand Function Magnetic Stimulation System, Biofeedback Stimulator, Portable Biofeedback Stimulator, applied in the rehabilitation department, pediatric rehabilitation department, neurology department, orthopedics department, and geriatrics department.
In addition, Medlander also enhances the competitiveness of its rehabilitation product lines through mergers, acquisitions, and investments.Horizontal Layout in Other Medical Aesthetics and Related TracksSince 2019, investments have been made successively.Oubao Xiang, Yisu Medical, Aotong Laser, Xiaofu Technology, layout in injection molding parts, female reproductive rehabilitation products, laser equipment, and technology-based skin testing, laying the foundation for long-term health and beauty strategic planning.On October 24, 2023, Medlander completed the acquisition of 100% equity in Shanghai Aotong Laser.It is reported that Aotong Laser is a high-tech enterprise specializing in the development, production, and operation of laser medical equipment. It is committed to providing users across China and other regions worldwide with comprehensive laser, photon medical, and beauty solutions, including high-performance equipment, full technical support, and continuous clinical support.
On January 26, 2024, Medlander completed the acquisition of 55% equity in Hangzhou Xiaofu Technology.It is reported that Xiaofu Technology is a company that has taken the lead in completing the deep integration of imaging acquisition hardware, application software, underlying analysis algorithms, and business scenarios in the fields of 3D facial modeling and AI skin and morphology analysis. It provides customers with integrated medical aesthetics digital diagnosis and solutions. Its core product, "Meiji 3D Skin Analyzer," now serves more than 1,200 leading medical aesthetics institutions across China.
On June 6, 2024, the overall structural construction of Medlander Medical Technology Inc.'s headquarters R&D and production base project was completed, achieving the topping out of the main structure.It is reported that the headquarters R&D and production base of Medlander officially commenced construction on December 31, 2022. Covering an area of 44 mu, with a total building area of 90,000 square meters and a total investment exceeding 500 million yuan, the park integrates R&D, production, assembly, debugging, warehousing, office, and living facilities.
July 5, 2024Medlander andBeautiful Land signs strategic cooperation agreement, Both parties will join hands to deepen cooperation in sharing resources for the research and development of women's gynecological anti-aging, jointly promoting the industry to a higher level. It is reported that both partiesWill share gynecological anti-aging research achievements, technologies, and market information, promote industry technological innovation and industrial upgrading, and provide more professional and personalized solutions for female customers.
On February 26, 2025, Medlander released its 2024 earnings report, with total operating revenue of 423 million yuan, representing a year-on-year increase of 24.02%.Operating profit of 113 million yuan, a year-on-year increase of 10.06%; total profit of 123 million yuan, a year-on-year increase of 21.66%. It is reported that, inFrom 2021 to 2023, the company's revenues were 342 million yuan, 377 million yuan, and 341 million yuan, representing year-on-year growth of 1.52%, 10.32%, and -9.57%, respectively.
